Long-acting injection a shot in the arm for GSK’s HIV business

A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker’s key HIV business.

…read more

Discover Tomorrow’s Winning Stocks!
Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News